CN111990463A - 一种牛初乳复合粉 - Google Patents
一种牛初乳复合粉 Download PDFInfo
- Publication number
- CN111990463A CN111990463A CN201910446767.XA CN201910446767A CN111990463A CN 111990463 A CN111990463 A CN 111990463A CN 201910446767 A CN201910446767 A CN 201910446767A CN 111990463 A CN111990463 A CN 111990463A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- vitamin
- bovine colostrum
- whey protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 130
- 210000003022 colostrum Anatomy 0.000 title claims abstract description 42
- 235000021277 colostrum Nutrition 0.000 title claims abstract description 42
- 241000283690 Bos taurus Species 0.000 title claims abstract description 41
- 239000002131 composite material Substances 0.000 title claims abstract description 29
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 40
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 40
- 235000021119 whey protein Nutrition 0.000 claims abstract description 39
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 32
- 239000000944 linseed oil Substances 0.000 claims abstract description 32
- -1 fatty acid ester Chemical class 0.000 claims abstract description 27
- 229920001202 Inulin Polymers 0.000 claims abstract description 23
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 23
- 229940029339 inulin Drugs 0.000 claims abstract description 23
- 239000003094 microcapsule Substances 0.000 claims abstract description 23
- 235000018102 proteins Nutrition 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 241000251468 Actinopterygii Species 0.000 claims abstract description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 17
- 239000000194 fatty acid Substances 0.000 claims abstract description 17
- 229930195729 fatty acid Natural products 0.000 claims abstract description 17
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 16
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 16
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 13
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 13
- 229960005055 sodium ascorbate Drugs 0.000 claims abstract description 13
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims abstract description 13
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 12
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 12
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 11
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 10
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 10
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 10
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 10
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims abstract description 10
- 229940013618 stevioside Drugs 0.000 claims abstract description 10
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019202 steviosides Nutrition 0.000 claims abstract description 10
- 229920000881 Modified starch Polymers 0.000 claims abstract description 9
- 239000004368 Modified starch Substances 0.000 claims abstract description 9
- 235000019426 modified starch Nutrition 0.000 claims abstract description 9
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 9
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 9
- 235000010378 sodium ascorbate Nutrition 0.000 claims abstract description 9
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 5
- 244000068988 Glycine max Species 0.000 claims abstract description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 15
- 235000010755 mineral Nutrition 0.000 claims description 15
- 239000011707 mineral Substances 0.000 claims description 15
- 229940088594 vitamin Drugs 0.000 claims description 13
- 229930003231 vitamin Natural products 0.000 claims description 13
- 235000013343 vitamin Nutrition 0.000 claims description 13
- 239000011782 vitamin Substances 0.000 claims description 13
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- 229930003451 Vitamin B1 Natural products 0.000 claims description 5
- 229930003779 Vitamin B12 Natural products 0.000 claims description 5
- 229930003471 Vitamin B2 Natural products 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- 229960003563 calcium carbonate Drugs 0.000 claims description 5
- 235000010216 calcium carbonate Nutrition 0.000 claims description 5
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 5
- 239000011706 ferric diphosphate Substances 0.000 claims description 5
- 235000007144 ferric diphosphate Nutrition 0.000 claims description 5
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims description 5
- 229940036404 ferric pyrophosphate Drugs 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 5
- 239000001095 magnesium carbonate Substances 0.000 claims description 5
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 5
- 229960001708 magnesium carbonate Drugs 0.000 claims description 5
- 235000014380 magnesium carbonate Nutrition 0.000 claims description 5
- 229960003512 nicotinic acid Drugs 0.000 claims description 5
- 235000001968 nicotinic acid Nutrition 0.000 claims description 5
- 239000011664 nicotinic acid Substances 0.000 claims description 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 5
- 229960002477 riboflavin Drugs 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- 229960003495 thiamine Drugs 0.000 claims description 5
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 235000010374 vitamin B1 Nutrition 0.000 claims description 5
- 239000011691 vitamin B1 Substances 0.000 claims description 5
- 235000019163 vitamin B12 Nutrition 0.000 claims description 5
- 239000011715 vitamin B12 Substances 0.000 claims description 5
- 235000019164 vitamin B2 Nutrition 0.000 claims description 5
- 239000011716 vitamin B2 Substances 0.000 claims description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- 229940011671 vitamin b6 Drugs 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- 239000011670 zinc gluconate Substances 0.000 claims description 5
- 235000011478 zinc gluconate Nutrition 0.000 claims description 5
- 229960000306 zinc gluconate Drugs 0.000 claims description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000011755 sodium-L-ascorbate Substances 0.000 claims 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 23
- 108010073771 Soybean Proteins Proteins 0.000 abstract description 15
- 230000002980 postoperative effect Effects 0.000 abstract description 13
- 235000019710 soybean protein Nutrition 0.000 abstract description 13
- 230000001684 chronic effect Effects 0.000 abstract description 12
- 235000015097 nutrients Nutrition 0.000 abstract description 10
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 9
- 102000018358 immunoglobulin Human genes 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 239000013589 supplement Substances 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 3
- 235000021120 animal protein Nutrition 0.000 abstract description 3
- 108010064851 Plant Proteins Proteins 0.000 abstract description 2
- 230000001363 autoimmune Effects 0.000 abstract description 2
- 235000021118 plant-derived protein Nutrition 0.000 abstract description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 32
- 238000010521 absorption reaction Methods 0.000 description 17
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 15
- 229960004488 linolenic acid Drugs 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 206010010774 Constipation Diseases 0.000 description 7
- 210000001072 colon Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 208000002720 Malnutrition Diseases 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000001071 malnutrition Effects 0.000 description 6
- 235000000824 malnutrition Nutrition 0.000 description 6
- 208000015380 nutritional deficiency disease Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 208000007536 Thrombosis Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 229940114079 arachidonic acid Drugs 0.000 description 5
- 235000021342 arachidonic acid Nutrition 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 230000000050 nutritive effect Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010002198 Anaphylactic reaction Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 108010011619 6-Phytase Proteins 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003871 intestinal function Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229940085127 phytase Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 206010047675 Vocal cord polyp Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000006047 digesta Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 208000024466 platelet membrane fluidity Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000014515 polyp of vocal cord Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 210000000768 retinal photoreceptor cell outer segment Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007371 visceral function Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
Abstract
本发明公开了一种牛初乳复合粉，包括重量份数的如下组分：大豆分离蛋白粉15‑20份、磷脂粉3.1‑3.8份、浓缩乳清蛋白粉15‑19.21份、分离乳清蛋白粉15.7‑18.37份、牛初乳粉1.57‑2.15份、海洋鱼低聚肽粉2.81‑4.13份、菊粉6.27‑7.92份、麦芽糊精9‑11.5份、亚麻籽油微囊粉9.9‑13.2份、低聚果糖8.8‑12.65份、甜菊糖苷0.048‑0.072份，其中亚麻籽油微囊粉包含亚麻籽油、低聚半乳糖、变性淀粉、二氧化硅、单甘油脂肪酸酯、双甘油脂肪酸酯和抗坏血酸钠。本发明牛初乳复合粉将分离乳清蛋白粉、浓缩乳清蛋白粉、海洋鱼低聚肽、大豆分离蛋白粉四种蛋白结合使用，动植物蛋白协同作用，能全面补充人体所需的各种营养物质，帮助人体合成更多的免疫球蛋白，辅以牛初乳粉直接补充免疫球蛋白，有助于慢性病人、术后病人提升自身免疫能力。
Description
技术领域
本发明涉及乳制品技术领域，特别是涉及一种牛初乳复合粉。
背景技术
术后和慢性病人为特殊人群，其基础代谢率与正常人群差异较大。术后和慢性病人极其容易出现营养不良状况。术后或慢性病人出现营养不良的原因：1)病人高应激、高代谢或病人自身的代谢水平大多有部分障碍，常常使机体处于负氮平衡状态；2)病人常出现食欲减退、代谢紊乱、消化功能下降等问题，影响食物或某些营养素在胃肠道内正常消化吸收，造成病人营养不良。营养不良对慢性病、术后恢复的影响：1)细胞代谢异常，疾病修复速度减缓；2)损坏机体组织、器官的生理功能；3)降低机体免疫功能；4)减弱对疾病应激反应的抵抗能力；5)增加手术并发症和死亡率。
目前，尚未出现针对术后或慢性病人的产品来解决营养不良的问题。
发明内容
为了解决现有产品无法解决术后或慢性病人营养不良的问题，本发明的目的是提供一种牛初乳复合粉。
为了实现上述目的，本发明采用如下技术方案：一种牛初乳复合粉，包括重量份数的如下组分：大豆分离蛋白粉15-20份、磷脂粉3.1-3.8份、浓缩乳清蛋白粉15-19.21份、分离乳清蛋白粉15.7-18.37份、牛初乳粉1.57-2.15份、海洋鱼低聚肽粉2.81-4.13份、菊粉6.27-7.92份、麦芽糊精9-11.5份、亚麻籽油微囊粉9.9-13.2份、低聚果糖8.8-12.65份、甜菊糖苷0.048-0.072份，其中亚麻籽油微囊粉包含亚麻籽油、低聚半乳糖、变性淀粉、二氧化硅、单甘油脂肪酸酯、双甘油脂肪酸酯和抗坏血酸钠。
优选地，分离乳清蛋白粉、浓缩乳清蛋白粉和大豆分离蛋白粉的重量比为1:1:1。
分离乳清蛋白粉、浓缩乳清蛋白粉和大豆分离蛋白粉三种优质蛋白按1：1：1的比例有效结合，分离乳清蛋白粉分子结构更小，消化吸收更快，浓缩乳清蛋白粉吸收代谢速度在分离乳清蛋白与大豆分离蛋白之间，三种蛋白按1：1：1的比例有效结合以后，能更好的满足人体全天的需求量。
大豆分离蛋白，是以低温脱溶大豆粕为原料生产的一种全价蛋白类食品添加剂。大豆分离蛋白中蛋白质含量在90％以上，氨基酸种类有近20种，并含有人体必需氨基酸，属于全价蛋白质；大豆分离蛋白有助于防止动脉硬化，预防老年人易发的心血管疾病；热量低，易吸收；大豆分离蛋白去除了大豆中原有的营养抑制因子胰蛋白酶抑制剂，不用担心消化不良、胃胀气等不适反应。
大豆磷脂，主要含有卵磷脂、脑磷脂、肌醇磷脂、磷脂酰丝氨酸、磷脂酸及其他磷脂。磷脂是所有生命细胞的主要构成成分，对促进细胞组织的新陈代谢，维持细胞膜的正常结构与功能有重要的生理作用，卵磷脂能活化细胞，是构成人体的动力来源；卵磷脂能有效提高脑机能，卵磷脂能加强大脑神经元之间的信息传递，加快记忆，使思维能力和智商维持较高水平；卵磷脂能降低血清胆固醇水平，并能溶解残留在血管壁上的胆固醇，从而起到预防心脑血管疾病功效；保护肝脏免受酒精、香烟、药物、病毒及有毒物质的伤害，可维持正常肝功能；卵磷脂与微生物E具有相辅相成作用，能增强抗氧化活性，能分解体内多余脂肪。
浓缩乳清蛋白粉，为超滤技术浓缩乳清中蛋白质，然后干燥制得的可溶性粉末。浓缩乳清蛋白粉易消化，生物利用率高；富含支链氨基酸，可作为能源物质提供能量；含大量的赖氨酸和精氨酸，能刺激代谢激素的分泌，促进肌肉生长；为半胱氨酸、甲硫氨酸等含硫氨基酸的良好来源，能维持体内的谷胱甘肽水平，发挥抗氧化作用；含谷氨酰胺，有助于肌糖原更新并缓解因手术疾病造成的免疫功能下降。
分离乳清蛋白，被称为蛋白之王，是在乳清蛋白的基础上浓缩制成浓缩乳清蛋白，经过进一步分离得到高纯度乳清蛋白，去掉了脂肪，分子结构更小，易消化吸收。
牛初乳，是母牛分娩后的最初几天所分泌的乳汁。牛初乳不仅含有丰富的营养物质，而且含有大量的免疫因子和生长因子，包括免疫球蛋白、乳铁蛋白、溶菌酶、类胰岛素生长因子、表皮生长因子。
海洋鱼低聚肽，是以无污染或污染相对较小的深海鱼的皮、骨为原料，精制加工而成。海洋鱼低聚肽粉溶解性好，常温下即可迅速溶解于水，形成均匀分散的溶液，吸收率高达95％以上。海洋鱼低聚肽粉具有如下优点：
1、呵护骨骼，使得钙质与骨细胞紧密结合，不会出现钙流失或退化；
2、延缓衰老，适时补充海洋鱼低聚肽粉，能有效解决皮肤及肌肉水分减少问题，能使皮肤保持年轻；
3、增加免疫力，调节内分泌、保护及强化内脏功能、激活细胞机能、结合免疫球蛋白、增加免疫力。
菊粉，是植物中储备性多糖，主要来源于植物。菊粉具有如下优点：
1)控制血脂，摄入菊粉可有效降低血清总胆固醇和低密度脂蛋白胆固醇，提高高密度脂蛋白/低密度脂蛋白比率，改善血脂状况；
2)降低血糖
菊粉是一种不会导致尿中葡萄糖升高的碳水化合物。它在肠道的上部不会被水解成单糖，因而不会升高血糖水平和胰岛素含量；
3)促进矿物质的吸收
菊粉促进矿物质元素吸收的主要机制：a、菊粉在结肠发酵生成的短链脂肪使其黏膜上的隐窝变浅，隐窝细胞增多从而增大了吸收面积，盲肠静脉更发达；b、发酵所产生的酸降低结肠pH，使得许多矿物质的溶解度、生物有效性得以提高，特别是短链脂肪酸可以刺激结肠粘膜细胞的生长，提高肠粘膜的吸收能力；c、菊粉能促进一些微生物分泌植酸酶，植酸酶能使与植酸螯合的金属离子释放出来，促进其吸收；d、发酵生成的某些有机酸可与金属离子螯合，促进金属离子吸收。
4)调节肠道微生物菌群，改善肠道健康，防止便秘
菊粉是一种天然的水溶性膳食纤维，几乎不能被胃酸水解和消化，只有在结肠被有益微生物利用，从而改善肠道环境。
5)抑制有毒发酵产物的生成，保护肝脏，预防结肠癌
食物经消化吸收后到达结肠，在肠道腐生菌的作用下，可产生许多有毒的代谢产物，而菊粉在结肠被发酵产生的短链脂肪酸能够降低结肠pH，抑制腐生菌的生长，减少有毒产物的生成，减少其对肠壁的刺激。
6)防止便秘及治疗肥胖症
减少食物在胃肠的停留时间，增加粪便量，有效地治疗便秘。减肥作用是基于菊粉提高内容物的黏度，降低食物从胃进入小肠的速度，从而降低饥饿感，减少食物的摄食量。
7)抗抑郁作用
菊粉中有少量的低聚果糖，低聚果糖可使大脑神经细胞营养因子表达升高，对皮质酮诱导的神经元损作有很好的保护作用，具有抗抑郁作用。
麦芽糊精，作为碳水化合物，防止蛋白糖易生，辅助蛋白吸收，避免蛋白质吸收不充分。
亚麻籽油是从纯植物亚麻籽提取的油类。亚麻籽油中含有α-亚麻酸，α-亚麻酸是人体必需脂肪酸，是构成人体组织细胞的主要成分，在体内不能合成，α-亚麻酸在人体内可转化为EPA、DPA、DHA，有抗血栓、降血脂等作用。人体一旦缺乏，即会引起机体脂质代谢紊乱，导致免疫力降低、健忘、疲劳、视力减退、动脉粥样硬化等症状的发生。这一点已经被国内外科学家所证实，并被世界营养学界所公认。因此，食用亚麻籽油，对高血压病人，肥胖人和脑栓塞，心肌梗塞、肾病患者都有较好效果。
α-亚麻酸被国际医学界、营养学界所公认八大功效：
1、预防心脑血管病。由于血栓形成，血管发生堵塞，组织细胞得不到氧气补充和营养成份的供应，最终会导致死亡。在心脏冠状动脉和脑血管处易形成血栓，引起心肌梗塞和脑梗塞。人们已经知道促成血栓形成的重要因素是血小板凝集的过程。α-亚麻酸可以改变血小板膜流动性，从而改变血小板对刺激的反应性及血小板表面受体的数目。因此，能有效防止血栓的形成。
2、降血脂：α-亚麻酸的代谢产物对血脂代谢有温和的调节作用，能促进血浆低密度脂蛋白(LDL)向高密度脂蛋白(HDL)的转化，使低密度脂蛋白(LDL)降低，高密度脂蛋白(HDL)升高，从而达到降低血脂，防止动脉粥样硬化的目的。
3、降低临界性高血压：血压在145/90mmHg～160/95mmHg之间叫临界性高血压，是初期性高血压。若长期使用降压药，易引起许多不良反应。α-亚麻酸的代谢产物可以扩张血管，增强血管弹性，从而起到降压作用。
4、抑制癌症的发生和转移：正常的体细胞会因为机体功能的失衡而产生病变，而癌细胞形成后会产生大量的能抑制多种免疫细胞机能的二烯前列腺素，降低人体免疫系统功能，使癌细胞得以增殖和转移。α-亚麻酸的代谢产物可以直接减少致癌细胞生成数量，同时削弱血小板的凝集作用，抑制二烯前列腺素的生成，恢复及提高人体的免疫系统功能，从而能有效地防止癌症形成以及抑制其转移。爱斯基摩人乳腺癌的发病率很低，是因为他们大量进食鱼类或其它海产品，脂肪摄取量虽然大，但不饱和脂肪酸成份多，主要是n-3系脂肪酸(α-亚麻酸)，因此其癌症的发病率极低。
5、抑制过敏反应、抗炎作用：α-亚麻酸可降低多核白细胞(RMNS)及肥大细胞膜磷脂中花生四烯酸(AA)的含量，使过敏反应发生时AA释放量减少，从而降低LT4(白三烯)的生成；代谢产物EPA还有与AA竞去饱和酶的作用；α-亚麻酸对过敏反应的中间体PAF(血小板凝集活化因子)有抑制作用。所以认为，α-亚麻酸对过敏反应及炎症有抑制效果。临床研究得出，牛皮癣的发病机理主要由花生四烯酸代谢紊乱所致，而摄入一定量的EPA后症状得以减轻。大量的动物实验证明，体质的过敏反应亢进是由摄入含α-亚麻酸食物的缺乏引起的
6、抑制衰老：随着年龄的增加，体内各种自由基的数目不断增多，而谷胱甘肽过氧化物酶(GSH-Px)及超氧化物歧化酶(SOD)数量逐渐降低，活性逐渐减弱，因此自由基代谢产物丙二醛(MDA)的生成增多，使细胞受到损伤，组织器官功能下降。服用α-亚麻酸后，GSH-Px及SOD活性增加，MDA的生成减少，揭示α-亚麻酸有抗衰老作用。
7、增强智力：健全的大脑绝对不可缺少脂肪酸，特别是α-亚麻酸，脂肪酸为大脑提供所需的能量，人脑之所以能从事高度复杂的工作，离不开高质量的脂肪酸。18个碳原子的α-亚麻酸可以进一步延伸碳链，增加双键个数，生成EPA和DHA。DHA在脑神经细胞中大量集存，是大脑形成和智商开发的必需营养素。
8、保护视力：视网膜中视细胞外节含DHA特别多。如果DHA缺乏，视力就会下降，视网膜反射能恢复时间延长。α—亚麻酸代谢产物DHA，可以提高和保护视力。
微囊粉是利用微囊技术，经高品质壁材将固体、液体或气体物质包裹形成的一种粉末状物质。采用微囊粉包裹技术，达到易保存、保质期长、营养不流失的效果。
低聚果糖、低聚半乳糖作为益生元，具有如下作用：
1、作为膳食补充剂；
2、减轻便秘，益生元为在大肠中发酵的碳水化合物，缩短了消化物在大肠中的逗留时间，有助于缓解便秘；
3、调理细菌平衡，益生元可以帮助大肠在经过抗生素、腹泻、压力或其他药物的干扰后恢复肠内细菌平衡；
4、增强免疫，通过改变肠菌落从而影响免疫系统，通过竞争性抑制，降低有害菌数量。
甜菊糖苷，是一种从菊科草本植物甜叶菊(或称甜菊叶)中精提的新型天然甜味剂。
其中，所述牛初乳复合粉还包括0.017-0.023重量份的复合矿物质和0.005-0.007重量份的复合维生素。其中，所述复合矿物质包括碳酸钙、碳酸镁、葡萄糖酸锌、焦磷酸铁。
其中，所述复合维生素包括L-抗坏血酸钠、牛磺酸、维生素E、烟酸、维生素B2、维生素A、D-泛酸钙、叶酸、维生素B6、维生素B1、维生素D、β-胡萝卜素、维生素B12。
复合维生素和复合矿物质，可促进术后病人营养吸收，钙质吸收，有助于帮助机体自身修复和维持肠道正常。
本发明将分离乳清蛋白粉、浓缩乳清蛋白粉、大豆分离蛋白粉三种蛋白结合使用，双动物蛋白+植物蛋白协同作用，营养价值高，且含有多种活性成分，能全面补充人体所需的各种营养物质，帮助人体合成更多的免疫球蛋白，在本发明中起君的作用。
本发明辅以牛初乳粉直接补充免疫球蛋白，与人体自身合成免疫球蛋白相结合，有助于更好地提升慢性病人、术后病人自身免疫能力，有利于组织的形成和生长，更有助于修复人体组织器官。同时辅以海洋鱼低聚肽粉，优质海洋蛋白更有助于促进伤口的修复，加快手术愈合，减轻患者痛苦，此二味为臣药。
本发明佐以菊粉、低聚果糖和低聚半乳糖协同作用改善肠道功能，避免蛋白质吸收代谢时造成腹泻和便秘，复合碳水化合物分阶段释放，长效功能，避免蛋白质吸收不充分。佐以复合维生素和复合矿物质，能快速有效地补充慢性病人、术后病人所需的营养物质，帮助病人更快速地进行自我恢复进程，避免营养缺失，减少术后病毒侵害，减轻患者痛苦，提高慢性病人康复速度。
本发明将大豆磷脂粉与亚麻籽油微囊粉二者结合，是本发明中的使药。能有效提供血液携氧量，活化细胞；将营养物质通过血液细胞传送至将人体各项组织，协同促进人体对上述物质的吸收和利用，引导上述诸味营养物质发挥更好的作用；更好的促进细胞组织的新陈代谢，维持细胞膜的正常结构与功能，降低血清胆固醇水平，并能溶解残留在血管壁上的胆固醇，预防心脑血管疾病；保护肝脏免受药物、病毒及有毒物质的伤害；预防血液粘稠，排除体内多余脂肪，调节激素平衡，减少自由基的产生。
本发明将上述营养物质科学比例搭配，能帮助病人更快速地促进自我恢复进程，减少术后病毒侵害，减轻患者痛苦；提高慢性病人康复速度。是术前术后病人，慢性病人康复过程中不可缺少的营养物质。
与现有技术相比，本发明实现的有益效果：本发明牛初乳复合粉将分离乳清蛋白粉、浓缩乳清蛋白粉、大豆分离蛋白粉三种蛋白结合使用，动植物蛋白协同作用，营养价值高，且含有多种活性成分，能全面补充人体所需的各种营养物质，帮助人体合成更多的免疫球蛋白，辅以牛初乳粉直接补充免疫球蛋白，有助于慢性病人、术后病人提升自身免疫能力；海洋鱼低聚肽粉含优质海洋蛋白，有助于促进伤口的修复，加快手术愈合，减轻患者痛苦；本发明牛初乳复合粉将菊粉、低聚果糖和低聚半乳糖协同作用改善肠道功能，防止腹泻和便秘，复合碳水化合物分阶段释放，长效功能，避免蛋白质吸收不充分；本发明牛初乳复合粉采用亚麻籽油微囊粉排除体内多余脂肪，调节激素平衡，减少自由基的产生，辅以人体所需的各项维生素和矿物质，能快速有效地补充慢性病人、术后病人所需的营养物质，帮助病人更快速地进行自我恢复进程，减少术后病毒侵害，减轻患者痛苦。
具体实施方式
以下由特定的具体实施例说明本发明的实施方式，熟悉此技术的人士可由本说明书所揭露的内容轻易地了解本发明的其他优点及功效。
实施例1
一种牛初乳复合粉，包括重量份数的如下组分：大豆分离蛋白粉15份、磷脂粉3.1份、浓缩乳清蛋白粉15份、分离乳清蛋白粉15.7份、牛初乳粉1.57份、海洋鱼低聚肽粉2.81份、菊粉6.27份、麦芽糊精9份、亚麻籽油微囊粉10.45份、低聚果糖9.35份、甜菊糖苷0.06份，其中亚麻籽油微囊粉包含亚麻籽油、低聚半乳糖、变性淀粉、二氧化硅、单甘油脂肪酸酯、双甘油脂肪酸酯和抗坏血酸钠。
实施例2
一种牛初乳复合粉，包括重量份数的如下组分：大豆分离蛋白粉17份、磷脂粉3.1份、浓缩乳清蛋白粉16份、分离乳清蛋白粉15.8份、牛初乳粉1.6份、海洋鱼低聚肽粉3.4份、菊粉6.6份、麦芽糊精10份、亚麻籽油微囊粉9.9份、低聚果糖8.8份、甜菊糖苷0.057份，其中亚麻籽油微囊粉包含亚麻籽油、低聚半乳糖、变性淀粉、二氧化硅、单甘油脂肪酸酯、双甘油脂肪酸酯和抗坏血酸钠。
实施例3
一种牛初乳复合粉，包括重量份数的如下组分：大豆分离蛋白粉16份、磷脂粉3.1份、浓缩乳清蛋白粉17.5份、分离乳清蛋白粉18.37份、牛初乳粉1.73份、海洋鱼低聚肽粉3.3份、菊粉6.93份、麦芽糊精10.5份、亚麻籽油微囊粉11.55份、低聚果糖11.55份、甜菊糖苷0.48份，其中亚麻籽油微囊粉包含亚麻籽油、低聚半乳糖、变性淀粉、二氧化硅、单甘油脂肪酸酯、双甘油脂肪酸酯和抗坏血酸钠。
实施例4
一种牛初乳复合粉，包括重量份数的如下组分：大豆分离蛋白粉16.5份、磷脂粉3.4份、浓缩乳清蛋白粉19.21份、分离乳清蛋白粉16.5份、牛初乳粉1.9份、海洋鱼低聚肽粉3.4份、菊粉7.92份、麦芽糊精10份、亚麻籽油微囊粉11份、低聚果糖12.65份、甜菊糖苷0.06份、复合矿物质0.023份、复合维生素0.007份，其中亚麻籽油微囊粉包含亚麻籽油、低聚半乳糖、变性淀粉、二氧化硅、单甘油脂肪酸酯、双甘油脂肪酸酯和抗坏血酸钠，复合矿物质包括碳酸钙、碳酸镁、葡萄糖酸锌、焦磷酸铁，复合维生素包括L-抗坏血酸钠、牛磺酸、维生素E、烟酸、维生素B2、维生素A、D-泛酸钙、叶酸、维生素B6、维生素B1、维生素D、β-胡萝卜素、维生素B12。
实施例5
一种牛初乳复合粉，包括重量份数的如下组分：大豆分离蛋白粉20份、磷脂粉3.8份、浓缩乳清蛋白粉17.0份、分离乳清蛋白粉17份、牛初乳粉2.15份、海洋鱼低聚肽粉4.13份、菊粉7.6份、麦芽糊精11.5份、亚麻籽油微囊粉13.2份、低聚果糖11.55份、甜菊糖苷0.072份、复合矿物质0.017份、复合维生素0.005份，其中亚麻籽油微囊粉包含亚麻籽油、低聚半乳糖、变性淀粉、二氧化硅、单甘油脂肪酸酯、双甘油脂肪酸酯和抗坏血酸钠，复合矿物质包括碳酸钙、碳酸镁、葡萄糖酸锌、焦磷酸铁，复合维生素包括L-抗坏血酸钠、牛磺酸、维生素E、烟酸、维生素B2、维生素A、D-泛酸钙、叶酸、维生素B6、维生素B1、维生素D、β-胡萝卜素、维生素B12。
实施例6
一种牛初乳复合粉，包括重量份数的如下组分：大豆分离蛋白粉18.1份、磷脂粉3.2份、浓缩乳清蛋白粉18.1份、分离乳清蛋白粉18.1份、牛初乳粉1.8份、海洋鱼低聚肽粉3.5份、菊粉7.6份、麦芽糊精11.5份、亚麻籽油微囊粉10份、低聚果糖11.55份、甜菊糖苷0.072份、复合矿物质0.017份、复合维生素0.005份，其中亚麻籽油微囊粉包含亚麻籽油、低聚半乳糖、变性淀粉、二氧化硅、单甘油脂肪酸酯、双甘油脂肪酸酯和抗坏血酸钠，复合矿物质包括碳酸钙、碳酸镁、葡萄糖酸锌、焦磷酸铁，复合维生素包括L-抗坏血酸钠、牛磺酸、维生素E、烟酸、维生素B2、维生素A、D-泛酸钙、叶酸、维生素B6、维生素B1、维生素D、β-胡萝卜素、维生素B12。
试验例1
挑选肺癌行胸腔镜下肺叶切除术患者20名，随机分成对照组(n＝10)、试验组(n＝10)，试验组使用实施例1制备的牛初乳复合粉，剂量为20g/60kg/d，对照组使用20g/60kg/d的水。从术后第1天开始添加，测定术后第1天、第10天TF、Hb、IgA和ALB指标，结果如表1。
表1
如表1所示，本实施例1制备的牛初乳复合粉可明显改善肺癌行胸腔镜下肺叶切除术患者的营养状况，提高患者免疫力。
试验例2
覃先生，男，土家族，74周岁，湖北省鹤峰县财政局退休干部。2018年9月分别在鹤峰县人民医院、恩施民院附属医院检查并经湖北省相关专家会诊确认为肝癌晚期，腹腔有积水。医院表示不愿收治，只是开具一些常规药物在家疗养，病情一直未见好转。2018年11月28日，开始食用实施例2制备的牛初乳复合粉，每天早中晚各1包。2019年3月25日在重庆万州三峡医院检查，甲胎蛋白数值200多(原数值10000多)，肝腹水已经消失，转氨酶数值100多，白蛋白略偏低(较以前大幅提升)；疲劳感较以前明显减轻，大便恢复接近正常(原来有些拉稀)，夜间易醒状态明显改善。
试验例3
胡女士，52岁，2018年10月做了声带息肉手术一直恢复不好，声音还是沙哑。(以前也曾做过2次手术都复发)自从2019年1月份开始食用实施例3的牛初乳复合粉，效果非常明显，不再沙哑，体力也提高了，睡眠质量提升，胃口增强。
上述实施例仅例示性说明本发明的原理及其功效，而非用于限制本发明。任何熟悉此技术的人士皆可在不违背本发明的精神及范畴下，对上述实施例进行修饰或改变。因此，举凡所属技术领域中具有通常知识者在未脱离本发明所揭示的精神与技术思想下所完成的一切等效修饰或改变，仍应由本发明的权利要求所涵盖。
Claims (4)
1.一种牛初乳复合粉，其特征在于，包括重量份数的如下组分：大豆分离蛋白粉15-20份、磷脂粉3.1-3.8份、浓缩乳清蛋白粉15-19.21份、分离乳清蛋白粉15.7-18.37份、牛初乳粉1.57-2.15份、海洋鱼低聚肽粉2.81-4.13份、菊粉6.27-7.92份、麦芽糊精9-11.5份、亚麻籽油微囊粉9.9-13.2份、低聚果糖8.8-12.65份、甜菊糖苷0.048-0.072份，其中亚麻籽油微囊粉包含亚麻籽油、低聚半乳糖、变性淀粉、二氧化硅、单甘油脂肪酸酯、双甘油脂肪酸酯和抗坏血酸钠。
2.如权利要求1所述的牛初乳复合粉，其特征在于，所述牛初乳复合粉还包括0.017-0.023重量份的复合矿物质和0.005-0.007重量份的复合维生素。
3.如权利要求2所述的牛初乳复合粉，其特征在于，所述复合矿物质包括碳酸钙、碳酸镁、葡萄糖酸锌、焦磷酸铁。
4.如权利要求2所述的牛初乳复合粉，其特征在于，所述复合维生素包括L-抗坏血酸钠、牛磺酸、维生素E、烟酸、维生素B2、维生素A、D-泛酸钙、叶酸、维生素B6、维生素B1、维生素D、β-胡萝卜素、维生素B12。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910446767.XA CN111990463A (zh) | 2019-05-27 | 2019-05-27 | 一种牛初乳复合粉 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910446767.XA CN111990463A (zh) | 2019-05-27 | 2019-05-27 | 一种牛初乳复合粉 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111990463A true CN111990463A (zh) | 2020-11-27 |
Family
ID=73461662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910446767.XA Pending CN111990463A (zh) | 2019-05-27 | 2019-05-27 | 一种牛初乳复合粉 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111990463A (zh) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112425658A (zh) * | 2020-11-30 | 2021-03-02 | 黑龙江八一农垦大学 | 一种牛初乳制品及其制备方法和应用 |
| CN113424961A (zh) * | 2021-06-17 | 2021-09-24 | 广州雪利昂生物科技有限公司 | 一种肺科营养素 |
| CN114504052A (zh) * | 2022-03-04 | 2022-05-17 | 桂林智仁食品工业有限公司 | 一种易吸收蛋白质粉及其制备方法 |
| CN114586987A (zh) * | 2022-03-10 | 2022-06-07 | 山东若尧特医食品有限公司 | 一种特殊医学用途蛋白质组件配方食品及制备方法和应用 |
| CN114668141A (zh) * | 2022-04-28 | 2022-06-28 | 浙江译美生物科技有限公司 | 一种复合营养粉 |
| CN115474688A (zh) * | 2021-06-16 | 2022-12-16 | 法尔玛国际健康管理有限公司 | 一种提升免疫力和增加肌肉的营养组合物 |
| CN115918914A (zh) * | 2022-12-01 | 2023-04-07 | 宝健（北京）生物技术有限公司 | 一种含复合蛋白的口服营养补充剂，制备及应用 |
| CN116725141A (zh) * | 2023-06-14 | 2023-09-12 | 深圳市小元圈科技有限公司 | 一种营养奶粉及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105029409A (zh) * | 2015-06-24 | 2015-11-11 | 芦冰 | 一种亚麻籽油微胶囊粉末及其制备方法 |
| CN105077270A (zh) * | 2015-07-16 | 2015-11-25 | 上海冬泽特医食品有限公司 | 一种营养强化复合粉、其制备方法及用途 |
| CN107912535A (zh) * | 2016-10-11 | 2018-04-17 | 李西平 | 一种牛初乳复合粉及其制备方法 |
| CN108477622A (zh) * | 2018-04-16 | 2018-09-04 | 赵成群 | 一种婴幼儿全功能营养组合物 |
-
2019
- 2019-05-27 CN CN201910446767.XA patent/CN111990463A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105029409A (zh) * | 2015-06-24 | 2015-11-11 | 芦冰 | 一种亚麻籽油微胶囊粉末及其制备方法 |
| CN105077270A (zh) * | 2015-07-16 | 2015-11-25 | 上海冬泽特医食品有限公司 | 一种营养强化复合粉、其制备方法及用途 |
| CN107912535A (zh) * | 2016-10-11 | 2018-04-17 | 李西平 | 一种牛初乳复合粉及其制备方法 |
| CN108477622A (zh) * | 2018-04-16 | 2018-09-04 | 赵成群 | 一种婴幼儿全功能营养组合物 |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112425658A (zh) * | 2020-11-30 | 2021-03-02 | 黑龙江八一农垦大学 | 一种牛初乳制品及其制备方法和应用 |
| CN115474688A (zh) * | 2021-06-16 | 2022-12-16 | 法尔玛国际健康管理有限公司 | 一种提升免疫力和增加肌肉的营养组合物 |
| CN113424961A (zh) * | 2021-06-17 | 2021-09-24 | 广州雪利昂生物科技有限公司 | 一种肺科营养素 |
| CN114504052A (zh) * | 2022-03-04 | 2022-05-17 | 桂林智仁食品工业有限公司 | 一种易吸收蛋白质粉及其制备方法 |
| CN114586987A (zh) * | 2022-03-10 | 2022-06-07 | 山东若尧特医食品有限公司 | 一种特殊医学用途蛋白质组件配方食品及制备方法和应用 |
| CN114586987B (zh) * | 2022-03-10 | 2024-02-27 | 山东若尧特医食品有限公司 | 一种特殊医学用途蛋白质组件配方食品及制备方法和应用 |
| CN114668141A (zh) * | 2022-04-28 | 2022-06-28 | 浙江译美生物科技有限公司 | 一种复合营养粉 |
| CN114668141B (zh) * | 2022-04-28 | 2023-10-03 | 浙江译美生物科技有限公司 | 一种复合营养粉 |
| CN115918914A (zh) * | 2022-12-01 | 2023-04-07 | 宝健（北京）生物技术有限公司 | 一种含复合蛋白的口服营养补充剂，制备及应用 |
| CN116725141A (zh) * | 2023-06-14 | 2023-09-12 | 深圳市小元圈科技有限公司 | 一种营养奶粉及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111990463A (zh) | 一种牛初乳复合粉 | |
| CN105054025B (zh) | 一种用于炎症性肠病患者的低脂低渗低渣型肠内营养粉剂 | |
| US6900173B2 (en) | Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery | |
| US20040253227A1 (en) | Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery | |
| US20210045423A1 (en) | Hydrolyzed Pea Protein-Based Nutrient Composition | |
| CN108685100B (zh) | 一种复合短肽粉配方及其制备方法 | |
| EP2100604A1 (en) | Medium chain dicarboxylic acids and their derivates and metabolic disorders | |
| US20230132388A9 (en) | Intact Pea Protein-Based Nutrient Composition | |
| WO2022016774A1 (zh) | 利于调节肠道、促进消化、改善便秘的组合物及其制备方法 | |
| CN107279296A (zh) | 一种适合糖尿病的配方食品及其制备方法 | |
| CN112385843A (zh) | 含复合益生元的均衡营养粉及其制备方法 | |
| CN107467193B (zh) | 一种以羊奶为基础的粉剂全营养特殊医学用途配方食品及其制备方法 | |
| WO2022165700A1 (zh) | 一种多肽营养粉及其制备方法 | |
| CN1943695A (zh) | 一种甲鱼制剂及其生产工艺 | |
| JP2007515417A (ja) | 創傷治癒のための栄養組成物 | |
| CN109043554A (zh) | 一种高膳食纤维的特殊食品及其制备方法 | |
| CN114947138A (zh) | 一种预防与改善钙缺乏病的乳钙组合物、其制法及应用 | |
| KR20200043555A (ko) | 다이어트용 보조식품 조성물 | |
| CN107874245A (zh) | 可避免乳糖不耐受和为乳糖不耐受人群提供营养的营养粉 | |
| NZ520605A (en) | Oral administration of a nutritional supplement containing at least 5.5% threonine increase mucin synthesis | |
| CN108348483A (zh) | 用于治疗或预防与组织中的超过正常数量的粒细胞相关联的疾病的可可多酚和可溶膳食纤维 | |
| CN113508841A (zh) | 一种营养丰富的早茶 | |
| CN108703373A (zh) | 一种七色营养素 | |
| WO2023076572A1 (en) | Nutritional composition for glucose support | |
| CN113575960B (zh) | 一种赤藓糖醇消化系统调节减肥代餐粉及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201127 |